Elisabeth Gulowsen Celius

List of Publications by Year
in descending order

121 papers	9,111 citations	101543 36 h-index	45317 90 g-index
136 all docs	136 docs citations	136 times ranked	13546 citing authors

#	Article	IF	Citations
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	27.8	2,400
2	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	21.4	1,213
3	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	12.6	710
4	Variation in interleukin 7 receptor Î± chain (IL7R) influences risk of multiple sclerosis. Nature Genetics, 2007, 39, 1108-1113.	21.4	441
5	Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nature Neuroscience, 2019, 22, 1617-1623.	14.8	358
6	Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics, 2015, 47, 1107-1113.	21.4	312
7	Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. American Journal of Human Genetics, 2013, 92, 854-865.	6.2	164
8	The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes and Immunity, 2009, 10, 11-14.	4.1	153
9	DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis. Nature Communications, 2018, 9, 2397.	12.8	147
10	Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens, 2004, 63, 237-247.	1.0	130
11	Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. European Journal of Human Genetics, 2009, 17, 1309-1313.	2.8	115
12	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
13	Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. Journal of the Neurological Sciences, 2000, 178, 132-135.	0.6	113
14	Depressive symptoms account for deficient information processing speed but not for impaired working memory in early phase multiple sclerosis (MS). Journal of the Neurological Sciences, 2004, 217, 211-216.	0.6	93
15	Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting. PLoS ONE, 2013, 8, e58643.	2.5	91
16	Cortical thickness and surface area relate to specific symptoms in early relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 402-414.	3.0	79
17	Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurology: Genetics, 2016, 2, e87.	1.9	76
18	Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurology, The, 2010, 9, 672-680.	10.2	70

#	Article	IF	Citations
19	The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. European Journal of Neurology, 2007, 14, 835-840.	3.3	68
20	IL-22RA2 Associates with Multiple Sclerosis and Macrophage Effector Mechanisms in Experimental Neuroinflammation. Journal of Immunology, 2010, 185, 6883-6890.	0.8	68
21	A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nature Communications, 2019, 10, 2236.	12.8	65
22	A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. European Journal of Human Genetics, 2010, 18, 502-504.	2.8	60
23	Killer immunoglobulinâ€like receptor ligand HLAâ€Bw4 protects against multiple sclerosis. Annals of Neurology, 2009, 65, 658-666.	5.3	55
24	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	3.0	55
25	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain, 2015, 138, 632-643.	7.6	54
26	Importance of Human Leukocyte Antigen (HLA) Class I and II Alleles on the Risk of Multiple Sclerosis. PLoS ONE, 2012, 7, e36779.	2.5	53
27	Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. Journal of Neurology, 2013, 260, 1481-1488.	3.6	50
28	No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Annals of Neurology, 2013, 73, 430-432.	5.3	46
29	Deep neural networks learn general and clinically relevant representations of the ageing brain. NeuroImage, 2022, 256, 119210.	4.2	46
30	Oligoclonal Band Status in Scandinavian Multiple Sclerosis Patients Is Associated with Specific Genetic Risk Alleles. PLoS ONE, 2013, 8, e58352.	2.5	45
31	Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study. BMC Neurology, 2014, 14, 196.	1.8	45
32	Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry. Frontiers in Neurology, 2021, 12, 693017.	2.4	45
33	The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes and Immunity, 2001, 2, 263-268.	4.1	44
34	Prevalence of multiple sclerosis among immigrants in Norway. Multiple Sclerosis Journal, 2015, 21, 695-702.	3.0	43
35	Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 660-668.	3.0	42
36	High prevalence and no latitude gradient of multiple sclerosis in Norway. Multiple Sclerosis Journal, 2014, 20, 1780-1782.	3.0	41

#	Article	IF	Citations
37	A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity. PLoS ONE, 2015, 10, e0135974.	2.5	41
38	Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus. Genes and Immunity, 2011, 12, 191-198.	4.1	40
39	Multiple sclerosis and seizures: incidence and prevalence over 40Âyears. Acta Neurologica Scandinavica, 2014, 130, 368-373.	2.1	39
40	Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 19-22.	1.9	39
41	Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. Multiple Sclerosis Journal, 2013, 19, 1028-1034.	3.0	38
42	Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients. PLoS ONE, 2018, 13, e0206511.	2.5	37
43	Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness. Frontiers in Neurology, 2015, 6, 18.	2.4	36
44	The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells. Genes and Immunity, 2016, 17, 118-127.	4.1	35
45	Low frequency of the diseaseâ€associated DRB1*15â€DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami. Tissue Antigens, 2007, 69, 299-304.	1.0	34
46	Two HLA class I genes independently associated with multiple sclerosis. Journal of Neuroimmunology, 2010, 226, 172-176.	2.3	30
47	X chromosome inactivation in females with multiple sclerosis. European Journal of Neurology, 2007, 14, 1392-1396.	3.3	29
48	Infections in patients with multiple sclerosis: Implications for disease-modifying therapy. Acta Neurologica Scandinavica, 2017, 136, 34-36.	2.1	29
49	Bone Turnover and Metabolism in Patients with Early Multiple Sclerosis and Prevalent Bone Mass Deficit: A Population-Based Case-Control Study. PLoS ONE, 2012, 7, e45703.	2.5	28
50	Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients. Journal of Neuroimmunology, 2005, 166, 197-201.	2.3	27
51	Chronic fatigue and depression due to multiple sclerosis: Immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways. Multiple Sclerosis and Related Disorders, 2020, 46, 102533.	2.0	27
52	Association of Genetic Markers with CSF Oligoclonal Bands in Multiple Sclerosis Patients. PLoS ONE, 2013, 8, e64408.	2.5	27
53	Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of Clinical and Translational Neurology, 2014, 1, 141-144.	3.7	26
54	Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. Multiple Sclerosis Journal, 2020, 26, 1569-1580.	3.0	26

#	Article	IF	Citations
55	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, 11, 4016.	12.8	26
56	The influence of <scp>THC</scp>:<scp>CBD</scp> oromucosal spray on driving ability in patients with multiple sclerosisâ€related spasticity. Brain and Behavior, 2018, 8, e00962.	2.2	25
57	Eye and hand motor interactions with the Symbol Digit Modalities Test in early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 585-589.	2.0	24
58	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335.	8.1	24
59	Fatigue and cognition: Pupillary responses to problemâ€solving in early multiple sclerosis patients. Brain and Behavior, 2017, 7, e00717.	2.2	24
60	Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis. Nature Genetics, 2010, 42, 469-470.	21.4	23
61	Socio-economic factors and immigrant population studies of multiple sclerosis. Acta Neurologica Scandinavica, 2015, 132, 37-41.	2.1	23
62	Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Multiple Sclerosis and Related Disorders, 2020, 43, 102146.	2.0	23
63	Genetic Association of Multiple Sclerosis with the Marker rs391745 near the Endogenous Retroviral Locus HERV-Fc1: Analysis of Disease Subtypes. PLoS ONE, 2011, 6, e26438.	2.5	22
64	Increased disease severity in nonâ€<scp>W</scp>estern immigrants with multiple sclerosis in <scp>O</scp>slo, <scp>N</scp>orway. European Journal of Neurology, 2013, 20, 1546-1552.	3.3	22
65	High prevalence and increasing incidence of multiple sclerosis in the Norwegian county of Buskerud. Acta Neurologica Scandinavica, 2017, 135, 412-418.	2.1	21
66	Normal antibody response after COVID-19 during treatment with cladribine. Multiple Sclerosis and Related Disorders, 2020, 46, 102476.	2.0	21
67	Association to the Glypican-5 gene in multiple sclerosis. Journal of Neuroimmunology, 2010, 226, 194-197.	2.3	20
68	The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521731990129.	1.0	18
69	High prevalence of fatigue in contemporary patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199982.	1.0	18
70	Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives. Patient Preference and Adherence, 2021, Volume 15, 15-27.	1.8	18
71	Perceptions of illness and its development in patients with multiple sclerosis: a prospective cohort study. Journal of Advanced Nursing, 2009, 65, 184-192.	3.3	17
72	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. Neuroscience Letters, 2012, 530, 155-160.	2.1	17

#	Article	IF	Citations
73	Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort. European Journal of Human Genetics, 2015, 23, 688-692.	2.8	17
74	Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. Multiple Sclerosis Journal, 2017, 23, 213-219.	3.0	17
75	Is the hygiene hypothesis relevant for the risk of multiple sclerosis?. Acta Neurologica Scandinavica, 2017, 136, 26-30.	2.1	17
76	Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Frontiers in Neurology, 2019, 10, 253.	2.4	17
77	The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression. Journal of Neurology, 2021, 268, 1330-1341.	3.6	17
78	Multiple Sclerosis Risk Allele in CLEC16A Acts as an Expression Quantitative Trait Locus for CLEC16A and SOCS1 in CD4+ T Cells. PLoS ONE, 2015, 10, e0132957.	2.5	16
79	Reduced perfusion in white matter lesions in multiple sclerosis. European Journal of Radiology, 2015, 84, 2605-2612.	2.6	16
80	Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10Âyears of disease - a case control study. BMC Neurology, 2016, 16, 252.	1.8	16
81	Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. Npj Genomic Medicine, 2017, 2, 24.	3.8	16
82	Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients. Journal of Neuroimmunology, 2003, 143, 101-106.	2.3	15
83	Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations. Journal of Neuroimmunology, 2006, 180, 193-198.	2.3	15
84	Polymorphisms of the BDNF gene show neither association with multiple sclerosis susceptibility nor clinical course. Journal of Neuroimmunology, 2012, 244, 107-110.	2.3	15
85	Incidence of cancer in multiple sclerosis before and after the treatment eraâ€“ a registry- based cohort study. Multiple Sclerosis and Related Disorders, 2021, 55, 103209.	2.0	15
86	The SH2D2A gene and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2008, 197, 152-158.	2.3	14
87	No association between multiple sclerosis and periodontitis after adjusting for smoking habits. European Journal of Neurology, 2015, 22, 588-590.	3.3	12
88	Magnetic resonance imaging perfusion is associated with disease severity and activity in multiple sclerosis. Neuroradiology, 2017, 59, 655-664.	2.2	11
89	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. Annals of Neurology, 2018, 84, 958-959.	5.3	10
90	Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. European Journal of Human Genetics, 2011, 19, 1100-1103.	2.8	9

#	Article	IF	Citations
91	No differential gene expression for CD4+ T cells of MS patients and healthy controls. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985690.	1.0	9
92	Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease. Journal of Neurology, 2019, 266, 1270-1271.	3.6	9
93	From genetic associations to functional studies in multiple sclerosis. European Journal of Neurology, 2016, 23, 847-853.	3.3	8
94	Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 687-698.	3.0	8
95	Prevalence of multiple sclerosis in rural and urban districts in Telemark county, Norway. Multiple Sclerosis and Related Disorders, 2020, 45, 102352.	2.0	8
96	Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. Journal of Neuroimmunology, 2014, 274, 174-179.	2.3	7
97	Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103812.	2.0	7
98	No influence on disease progression of non-HLA susceptibility genes in MS. Journal of Neuroimmunology, 2011, 237, 98-100.	2.3	6
99	Maternal education has significant influence on progression in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103052.	2.0	6
100	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. Multiple Sclerosis and Related Disorders, 2022, 57, 103389.	2.0	6
101	Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation. Journal of Neurology, 2022, 269, 3723-3734.	3.6	6
102	Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Multiple Sclerosis Journal, 2004, 10, 5-8.	3.0	5
103	Fatigue in multiple sclerosis is associated with socioeconomic factors. Multiple Sclerosis and Related Disorders, 2022, 64, 103955.	2.0	5
104	Quality of Life Improves with Alemtuzumab Over 6ÂYears in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2020, 9, 443-457.	3.2	4
105	Management of Severe Gravesâ€™ Hyperthyroidism in Pregnancy Following Immune Reconstitution Therapy in Multiple Sclerosis. Journal of the Endocrine Society, 2021, 5, bvab044.	0.2	4
106	Association of adverse childhood experiences with the development of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 645-650.	1.9	4
107	Comments on the review article â€˜Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decadesâ€™. Acta Neurologica Scandinavica, 2015, 132, 364-367.	2.1	3
108	State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. Neurology and Therapy, 2020, 9, 281-300.	3.2	3

#	Article	IF	Citations
109	The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort. Multiple Sclerosis and Related Disorders, 2022, 61, 103759.	2.0	3
110	Exploring Retinal Blood Vessel Diameters as Biomarkers in Multiple Sclerosis. Journal of Clinical Medicine, 2022, 11, 3109.	2.4	3
111	Coding region polymorphisms in T cell signal transduction genes. Prevalence and association to development of multiple sclerosis. Journal of Neuroimmunology, 2006, 177, 40-45.	2.3	2
112	Neurodegenerative Interplay of Cardiovascular Autonomic Dysregulation and the Retina in Early Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 507.	2.4	2
113	CD8+ T cell gene expression analysis identifies differentially expressed genes between multiple sclerosis patients and healthy controls. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732097851.	1.0	2
114	No significant differences in absenteeism or academic achievements in a Norwegian multiple sclerosis case control study. Multiple Sclerosis and Related Disorders, 2021, 54, 103141.	2.0	2
115	MYO9B polymorphisms in multiple sclerosis. European Journal of Human Genetics, 2009, 17, 840-843.	2.8	1
116	Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of Clinical and Translational Neurology, 2014, 1, 376-377.	3.7	1
117	Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS). Journal of Central Nervous System Disease, 2022, 14, 117957352110694.	1.9	1
118	Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. Journal of Neurology, 2022, 269, 5901-5909.	3.6	1
119	A follow-up study of Nordic multiple sclerosis candidate gene regions. Multiple Sclerosis Journal, 2007, 13, 584-589.	3.0	0
120	Involvement of the endogenous retroviral locus HERV-Fc1 on the human X-chromosome in multiple sclerosis. Retrovirology, 2011, 8, .	2.0	0
121	Breastfeeding and treatment of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 801-802.	3.0	0